Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA Says UK Approach To AI Regulation ‘Legislatively Light’, Unlike EU Proposals

Executive Summary

The UK’s medtech regulator is “going big on guidance” when it comes to artificial intelligence and software as a medical device, an expert from the agency has said, while legislation will be light in comparison to the EU’s planned AI Act.

You may also be interested in...



What Does The UK’s ‘Flexible’ Approach To AI Regulation Mean For Pharma?

The UK government says that its non-legislative approach to AI regulation will promote innovation and allow it to react quickly to changes in the ecosystem. But a life sciences lawyer warns that creating an uncertain regulatory environment could be problematic.

Merck’s Nuray Yurt Calls For Greater AI Education Among Regulators

Nuray Yurt, Merck’s business engagement and activation lead for digital data and analytics, told In Vivo about her hopes for the future of AI regulation and how stakeholders ought to reframe their understanding of the sector.

What The UK’s “Non-Statutory” AI Regulatory Framework Means For Medtech

The UK government has proposed a “pro-innovation” AI regulation strategy, which will utilize the expertise of existing regulators and avoid new legislation. But what does this mean for the medtech sector, and how does the UK approach differ from the EU’s AI Act?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel